The Health Insurance Administration recently notified them that these biosynthic drugs are dangerous.

On October 9, the National Health Insurance Administration, in its response to recommendation No. 6450 of the Third Session of the 13th National People's Congress, stated, "Our Bureau is studying the policy of centralized procurement of biological products, biosynthic drugs are not a restricted area for centralized procurement, and will conduct centralized procurement in due course, taking into account factors such as the similarity of biosynthic drugs, the stability of enterprise capacity and supply chain, and the clinical substitution of specific products."
Previously, the industry's highlights of the July 24 national harvesting conference had mentioned the inclusion of biologics in the collection, and the list of the top 500 varieties mentioned included a number of biologic drugs, including monoantial, insulin, etc.
According to insight database statistics, the 500 drug lists involved in the current competition of more adequate monoantigens include: lyxi monoantigen, clostoju monoantigen, beval bead monoantigen, Inasip (recombinant human type II. type tumor necrotic cause of the child-antibody fusion protein).
Insight database shows that at present, including the original research, these single resistance in the country have more than three enterprises approved: in addition, Adamo single resistance and Invlixi single resistance in the country has also involved a number of enterprises: attached: health insurance bureau original National Health Insurance Bureau of the Third Session of the 13th National People's Congress No. 6450 recommendation of the health insurance letter (2020) No. 83 as a thousand representative: you put forward "Recommendations on speeding up the level of medical security for diseases such as psoriasis" received from the State Health And Health Commission, the State Drug Administration, the answer is as follows: First, on the priority review and approval of drugs in August 2015, the State Council issued the "Opinion on the reform of the drug medical device review and approval system" (Guofa (2015) No. 44), proposed to improve the quality of review and approval, encourage research and creation of new drugs.
The Opinions on Resolving the Backlog of Drug Registration Applications (No. 19 of the Food and Drug Administration (2016) were issued in February 2016 to include drug registration applications in three categories and 17 cases in the priority review category, and to clarify the working procedures and work requirements for priority review and approval.
The newly revised Measures for the Administration of Drug Registration in 2020 also include innovative and improved new drugs in the scope of priority review and approval.
these policies play a positive role in meeting the clinical drug needs of patients with psoriasis.
, on the drug protection of psoriasis, the National Health Insurance Administration attaches great importance to the drug protection of patients with psoriasis.
the adjustment of the medical insurance drug catalogue focuses on the treatment of major diseases such as basic drugs, cancer and rare diseases, chronic diseases, children's medicines, emergency rescue drugs and other categories.
treatment of psoriasis has been included in the list of essential health insurance drugs.
At the same time, when the 2019 health care catalog was adjusted, the limited payment range of the recombinant human type II. type tumor necrosis subpopulation-antibody fusion protein in the original directory increased the adult severe plaque-like psoriasis adaptation, and added drugs such as Adamo monoanti, Invlisi monoantigen to the health insurance drug list through access negotiations.
nearly 20 drugs (Western medicines) in the current catalogue are available for the treatment of psoriasis.
In accordance with the Notice on the Inclusion of 2019 Negotiated Drugs in Category B, if any generic-named drug (generic) of other manufacturing enterprises is listed within the scope of the catalogue, the medical insurance department shall have the right to adjust the payment standards for medical insurance according to the price of generic drugs, and shall also have the right to include the generic-name drug in the scope of centralized procurement.
generics such as Symele (Adamo Monoanti) are included in medicare payments.
Basic medical insurance does not exclude any disease, including immunization-related chronic diseases, and persons who participate in basic medical insurance in accordance with the law and pay according to the provisions, regardless of the disease, the expenses adversity of medical treatment, in accordance with the provisions, may be paid by the basic medical insurance fund.
In the process of perfecting the basic medical insurance system, while doing a good job in ensuring the treatment of inpatients, the state guides all localities to include the outpatient medical expenses of some chronic diseases and special diseases, mainly in outpatient treatment, in accordance with the income and expenditure situation of the basic medical insurance fund.
Basic medical insurance shall be managed locally, and the level of financing and treatment shall be in accordance with the level of local economic development and medical consumption, and the scope and corresponding standards for outpatient chronic diseases, special diseases and corresponding standards paid by the co-ordination funds shall be determined by the co-ordination areas according to the local fund's ability to pay, the level of economic development and the level of medical consumption.
understood that some co-ordination areas have been psoriasis into the outpatient chronic special disease protection.
in accordance with the decision-making and deployment of the CPC Central Committee and the State Council, our Bureau has launched a new round of medical insurance catalog adjustment work, in August announced the "2020 National Health Insurance Drug Catalog Adjustment Work Programme."
the work programme, the 2020 catalogue adjustment is divided into five stages: preparation, enterprise declaration, expert review, negotiation and bidding, and publication of the results, with full work expected to be completed by the end of the year.
for the treatment of diseases such as psoriasis can be covered by the procedure.
In addition, our Bureau is studying the relevant policies of centralized procurement of biological products, biosynthic drugs are not a restricted area for centralized procurement, on the basis of considering the similarity of biosynthic drugs, the stability of enterprise capacity and supply chain, clinical substitution of specific products, etc., will be carried out in due course.
3. On psoriasis, the National Health and Health Commission continues to implement the National Health Literacy Promotion Initiative, vigorously develop the National Basic Public Health Service Health Education Program, and promote scientific health concepts, in accordance with the requirements of the Health China Initiative (2019-2030) and the National Health Literacy Promotion Action Plan (2014-2020).
Through popular science publicity, popularize healthy lifestyle, improve the health literacy of residents in scientific medical treatment, and promote the general public for psoriasis, severe spina bneitis, spinal muscular dystrophy and other diseases prevention and treatment to form a correct understanding.
next step, we will actively cooperate with relevant departments to focus on supporting the research and development of new drugs for psoriasis through new drugs, and promote the development and market of more clinically essential drugs.
At the same time, we will combine the needs of insured people to use drugs, health insurance financing capacity and other factors, improve the dynamic adjustment mechanism of the medical insurance catalog, through a strict expert evaluation process, the eligible drugs into the medical insurance catalog, and further reduce the burden of drug use patients.
thank you for your support and concern for the cause of health care.
.